Fremont, California
May 21,  2001

Pangene Corporation, a genomics-based pharmaceutical drug company producing pharmaceutical products and providing genomics services, announced today the launch of their secure
new genomics services web portal.

Access to Pangene's gene cloning and drug development platforms is available through the secure worldwide web-based genomics interface named DirectGenomics. Pangene utilized the services provided by DirectGenomics for its own development of a pipeline of biovalidated pharmaceutical drugs for DNA repair enzymes that are dysregulated in tumors. Pangene's drugs regulate these dysfunctional DNA repair enzymes in radio-resistant or chemo-resistant tumors and promote long-term survival. Pangene invented, patented and commercialized DNA damage repair and homologous DNA recombination processes enabling homologous gene isolation, homologous gene cloning, homologous gene recombination and drug exposed homologous gene profiling.

Pangene's technology platform enables rapid and high throughput gene cloning without using PCR. Gene clones generated from Pangene's gene cloning process are PCR-artifact free and expression-ready. Clients can submit their confidential gene sequences or ESTs online via Pangene's secure DirectGenomics Portal. Pangene produces full-length cDNA gene clones based on gene sequence information provided by clients and delivers these clones via FedEx. Each gene cloning order is identified by a unique tracking number and order progress and data is monitored securely online through the DirectGenomics portal.

Pangene currently offers guaranteed full length and economy gene cloning services as well as gene family cloning and interspecies gene cloning services. Account registration for DirectGenomics is complimentary at this time and can be immediately accessed through http://www.DirectGenomics.com.

Pangene is a privately held genomics-based pharmaceutical drug company commercializing DNA repair drugs and genomic services. Pangene uses its proprietary DNA repair enzyme mediated platform to isolate, clone, express, drug profile, and determine the functions of genes and their homologs. Pangene's technology platform enables determination of gene dysfunction
underlying disease and development of pharmaceutical drugs. Pangene discovered and patented the major human DNA repair genes and high value DNA repair enzyme targets which enabled the development of Repair Regulator Pharmaceutical Drugs (RRPDs) for radio-resistant or chemo-resistant tumors. RRPDS are conveniently formulated for use in combination with conventional
cancer therapies for more effective treatments of chemotherapeutic drug resistant and radiation resistant skin, breast, ovarian, colon, brain, prostate, pancreatic, head and neck and other tumors. The company operates in state-of-the-art facilities with full capabilities for drug development and genomic services.

Company news release
N2990a